| Business Type | Exporter, Supplier, Retailer |
| Usage | Treatment Of Unresectable Or Metastatic Melanoma With BRAF V600E Mutation,Metastatic Non-small Cell Lung Cancer With BRAF V600E Mutation,Anaplastic Thyroid Cancer With BRAF V600E Mutation |
| Country of Origin | India |
| Packaging Size | 120 Capsules In Box |
| Click to view more | |
Product Details
COMPOSITION:
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg
INDICATION:
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
LuciDabra is indicated, in combination with trametinib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.COMPOSITION:
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg
INDICATION:
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
LuciDabra is indicated, in combination with trametinib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.COMPOSITION:
Each LuciDabra Capsule contains: 88.88mg Dabrafenib mesylate equivalent to Dabrafenib……………….. 75mg
INDICATION:
LuciDabra is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
LuciDabra is indicated, in combination with trametinib, for:
· the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
· the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations and involvement of lymph node(s), following complete resection.
· the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
· the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.
Limitations of Use: LuciDabra is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF ATC.
* Currently we are not Accepting Orders for this Product.
